Bionexus Gene Lab Stock Market Value
| BGLC Stock | USD 5.10 1.53 23.08% |
| Symbol | BioNexus |
BioNexus Gene Lab Price To Book Ratio
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.19) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioNexus Gene 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioNexus Gene's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioNexus Gene.
| 04/20/2025 |
| 07/19/2025 |
If you would invest 0.00 in BioNexus Gene on April 20, 2025 and sell it all today you would earn a total of 0.00 from holding BioNexus Gene Lab or generate 0.0% return on investment in BioNexus Gene over 90 days. BioNexus Gene is related to or competes with Blue Biofuels, BioMark Diagnostics, Spectral Med, Microbix Biosystems, Nocopi Technologies, and SenesTech. BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diag... More
BioNexus Gene Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioNexus Gene's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioNexus Gene Lab upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 10.44 | |||
| Information Ratio | 0.109 | |||
| Maximum Drawdown | 301.65 | |||
| Value At Risk | (15.73) | |||
| Potential Upside | 23.17 |
BioNexus Gene Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioNexus Gene's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioNexus Gene's standard deviation. In reality, there are many statistical measures that can use BioNexus Gene historical prices to predict the future BioNexus Gene's volatility.| Risk Adjusted Performance | 0.1154 | |||
| Jensen Alpha | 3.06 | |||
| Total Risk Alpha | (0.94) | |||
| Sortino Ratio | 0.3598 | |||
| Treynor Ratio | 0.611 |
BioNexus Gene Lab Backtested Returns
BioNexus Gene is abnormally volatile given 3 months investment horizon. BioNexus Gene Lab secures Sharpe Ratio (or Efficiency) of 0.11, which signifies that the company had a 0.11 % return per unit of risk over the last 3 months. We were able to break down and interpolate twenty-nine different technical indicators, which can help you to evaluate if expected returns of 3.91% are justified by taking the suggested risk. Use BioNexus Gene Risk Adjusted Performance of 0.1154, downside deviation of 10.44, and Mean Deviation of 12.45 to evaluate company specific risk that cannot be diversified away. BioNexus Gene holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 6.36, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioNexus Gene will likely underperform. Use BioNexus Gene total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to analyze future returns on BioNexus Gene.
Auto-correlation | 0.22 |
Weak predictability
BioNexus Gene Lab has weak predictability. Overlapping area represents the amount of predictability between BioNexus Gene time series from 20th of April 2025 to 4th of June 2025 and 4th of June 2025 to 19th of July 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioNexus Gene Lab price movement. The serial correlation of 0.22 indicates that over 22.0% of current BioNexus Gene price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.22 | |
| Spearman Rank Test | 0.51 | |
| Residual Average | 0.0 | |
| Price Variance | 3.59 |
BioNexus Gene Lab lagged returns against current returns
Autocorrelation, which is BioNexus Gene stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting BioNexus Gene's stock expected returns. We can calculate the autocorrelation of BioNexus Gene returns to help us make a trade decision. For example, suppose you find that BioNexus Gene has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
BioNexus Gene regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If BioNexus Gene stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if BioNexus Gene stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in BioNexus Gene stock over time.
Current vs Lagged Prices |
| Timeline |
BioNexus Gene Lagged Returns
When evaluating BioNexus Gene's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of BioNexus Gene stock have on its future price. BioNexus Gene autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, BioNexus Gene autocorrelation shows the relationship between BioNexus Gene stock current value and its past values and can show if there is a momentum factor associated with investing in BioNexus Gene Lab.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:Check out BioNexus Gene Correlation, BioNexus Gene Volatility and BioNexus Gene Alpha and Beta module to complement your research on BioNexus Gene. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
BioNexus Gene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.